Recent News About Impax
-
The following cases categorized as "personal injury" were on the docket in the U.S. District Court for the Eastern District of Pennsylvania on Oct. 19. All case details are allegations only and should not be taken as fact:
-
The U.S. District Court for the Eastern District of Pennsylvania reported the following activity on Oct. 19 in the suits below:
-
The U.S. District Court for the Eastern District of Pennsylvania reported the following activity in the suit brought by Asbestos Workers Local Union No. 2 Welfare Fund against Endo Pharmaceuticals Inc. on Oct. 19.
-
On Oct. 29, the U.S. District Court for the Eastern District of Pennsylvania granted the Federal Trade Commission’s motion to dismiss an ongoing lawsuit with Watson Laboratories and Allergan Finance.
-
PHILADELPHIA - The Federal Trade Commission (FTC) thinks Endo Pharmaceuticals and other drug companies are violating antitrust laws when they pay other companies to delay bringing generic versions of their products to market.
-
SCRANTON – Rite Aid Corp. is claiming Medicis Pharmaceutical Corp., the manufacturer of acne treatment drug Solodyn, filed improper petitions and arranged unlawful agreements with their competitors to keep generic versions of Solodyn from reaching the market.
-
In what seems to be a fast-growing antitrust docket, another plaintiff has
-
The New York-based Rochester Drug Co-Operative has filed a federal antitrust action on
-
Specialty pharmaceutical company Impax Laboratories Inc., which has locations Philadelphia and Bucks County, Pa., announced Feb. 8 that it has settled all pending litigation with Shire LLC and Shire Laboratories Inc. relating to supply of its generic version of the drug Adderall, stating that Shire has agreed to make a one-time cash payment to Impax in the amount of $48 million.
